GT Biopharma Registers 14.6M Shares for Resale, Cites Going Concern Doubt

TL;DR

**GTBP's S-1 is a red flag for dilution and financial instability, signaling a tough road ahead for its immuno-oncology pipeline.**

AI Summary

GT Biopharma, Inc. (GTBP) filed an S-1 to register 14,589,546 shares of common stock for resale by selling stockholders, stemming from a May 2025 private placement. The offering includes 7,219,771 shares from the conversion of 3,277.78 Series L 10% Convertible Preferred Stock, 7,219,775 shares from vested warrants, and 150,000 shares from pre-funded warrants issued to PDPC Advisors Inc. The company will not receive any proceeds from the sale of these shares by the selling stockholders, but has received $3.0 million in gross proceeds from the exercise of Greenshoe Rights to date, which will be used for working capital. GT Biopharma is a clinical-stage biopharmaceutical company developing immuno-oncology products based on its proprietary TriKE® and Dual Targeting TriKE® platforms, designed to enhance natural killer (NK) cell activity against cancer. The company became fully remote on July 1, 2024, and its common stock trades on Nasdaq under 'GTBP', closing at $0.73 per share on October 23, 2025. The filing also highlights substantial doubt about the company's ability to continue as a going concern.

Why It Matters

This S-1 filing signals a significant dilution event for existing GTBP shareholders, as nearly 14.6 million shares are being registered for resale without the company receiving any direct proceeds from these sales. While the company did secure $3.0 million from Greenshoe Rights exercises, the primary purpose of this registration is to allow prior investors to monetize their holdings, potentially increasing selling pressure on the stock. For investors, this raises concerns about future stock performance and the company's ability to fund its clinical-stage immuno-oncology programs, especially given the explicit 'going concern' warning. Competitively, GT Biopharma's TriKE® platform is in a crowded biotech space, and its ability to advance drug candidates relies heavily on securing future capital.

Risk Assessment

Risk Level: high — The filing explicitly states, "We have evaluated the significance of the uncertainty regarding our financial condition in relation to our ability to meet our obligations, which has raised substantial doubt about our ability to cont[inue as a going concern]." This direct admission of substantial doubt about its ability to meet obligations, coupled with the fact that the company will receive no proceeds from the sale of 14,589,546 registered shares, indicates a very high financial risk.

Analyst Insight

Investors should exercise extreme caution and consider this S-1 a strong sell signal for GTBP. The substantial doubt about the company's going concern status, combined with significant potential dilution from the resale of 14,589,546 shares from which the company receives no proceeds, suggests severe financial headwinds. New investors should avoid, and current holders should re-evaluate their position given the high risk of further value erosion.

Financial Highlights

debt To Equity

N/A

revenue

N/A

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

N/A

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

N/A

Key Numbers

• 14,589,546 — Shares of Common Stock (Total shares registered for resale by selling stockholders)
• 7,219,771 — Conversion Shares (Shares issuable upon conversion of Series L Preferred Stock)
• 7,219,775 — Vesting Warrant Shares (Shares issuable upon exercise of vested warrants)
• 150,000 — Advisory Shares (Shares issuable upon exercise of pre-funded warrants to PDPC Advisors Inc.)
• $0.73 — Closing Sale Price (GTBP common stock price on October 23, 2025)
• $3.0 million — Gross Proceeds (Received from exercise of Greenshoe Rights to date)
• May 2025 — Date (Private placement occurred)
• July 1, 2024 — Date (Company became fully remote)

Key Players & Entities

• GT Biopharma, Inc. (company) — Registrant and clinical-stage biopharmaceutical company
• Michael Breen (person) — Chief Executive Officer of GT Biopharma, Inc.
• Alan A. Lanis, Jr. (person) — Legal counsel from Baker & Hostetler LLP
• PDPC Advisors Inc. (company) — Recipient of 150,000 pre-funded warrants
• Nasdaq Capital Market (regulator) — Stock exchange where GTBP is listed
• Securities and Exchange Commission (regulator) — Regulatory body for S-1 filing
• Dr. Jeffrey Miller (person) — Consulting Senior Medical Director and key opinion leader in NK cell biology
• University of Minnesota (company) — Collaborator with GT Biopharma on initial TriKE® work
• Baker & Hostetler LLP (company) — Legal firm representing GT Biopharma

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: The company has substantial doubt about its ability to continue as a going concern. This is primarily due to its history of operating losses and its need for future financing to fund its ongoing operations and clinical development programs. Without sufficient capital, GT Biopharma may be unable to meet its obligations.
• Dilution from Stock Issuances [high — financial]: The S-1 filing registers 14,589,546 shares for resale, including shares from convertible preferred stock and warrants. This significant number of shares, if sold, could substantially dilute existing shareholders' ownership percentage and potentially depress the stock price.
• Clinical Trial and Development Risks [high — operational]: As a clinical-stage biopharmaceutical company, GT Biopharma faces inherent risks in the development of its TriKE® and Dual Targeting TriKE® platforms. These include the possibility of failed clinical trials, regulatory delays, and the inability to obtain necessary approvals for its drug candidates, which could render its product pipeline valueless.
• FDA Approval Uncertainty [high — regulatory]: The success of GT Biopharma's products is contingent upon obtaining regulatory approval from the U.S. Food and Drug Administration (FDA) and other global health authorities. The lengthy and complex approval process, coupled with the potential for unexpected safety or efficacy issues, poses a significant risk to commercialization.
• Competition in Immuno-Oncology [medium — market]: The immuno-oncology space is highly competitive, with numerous established pharmaceutical companies and emerging biotechs developing similar therapies. GT Biopharma's ability to compete effectively will depend on the unique advantages and clinical success of its TriKE® platform compared to existing and pipeline treatments.
• Dependence on Future Financing [high — financial]: GT Biopharma relies on external financing to fund its research, development, and operational activities. The company's ability to secure additional funding in the future is not guaranteed and could be impacted by market conditions, clinical trial results, and overall investor sentiment.

Industry Context

GT Biopharma operates in the highly competitive immuno-oncology sector, a rapidly growing field focused on harnessing the patient's immune system to fight cancer. Key trends include the development of novel cell therapies, bispecific antibodies, and checkpoint inhibitors. The success of companies like GT Biopharma hinges on demonstrating superior efficacy and safety profiles for their proprietary platforms, such as TriKE®, against a backdrop of significant investment and innovation from both large pharmaceutical players and numerous emerging biotechs.

Regulatory Implications

As a clinical-stage biopharmaceutical company, GT Biopharma is subject to stringent regulatory oversight from bodies like the FDA. The development and approval process for its TriKE® platform candidates are lengthy, costly, and uncertain. Any delays, adverse findings in clinical trials, or failure to meet regulatory standards could significantly impact the company's ability to bring its products to market and achieve commercial success.

What Investors Should Do

1. Monitor clinical trial progress and data releases closely.
2. Assess the company's ability to secure future financing.
3. Evaluate the potential dilution from the registered shares.
4. Compare GT Biopharma's platform to competitors.

Key Dates

• 2024-07-01: Company became fully remote — Indicates a significant operational shift, potentially impacting costs and employee collaboration, but the long-term financial implications are not yet clear from this filing.
• 2025-05-01: Private placement occurred — This private placement is the source of the shares being registered for resale in the current S-1 filing, highlighting recent capital raising activities and the associated dilution.
• 2025-10-23: GTBP common stock closed at $0.73 — Provides a recent market valuation snapshot of the company's common stock, indicating a low share price which may reflect investor concerns or market sentiment.

Glossary

TriKE® platform

GT Biopharma's proprietary technology platform designed to develop immuno-oncology products that enhance natural killer (NK) cell activity against cancer. (This is the core technology of the company, and its success is critical to the company's future prospects and valuation.)

Dual Targeting TriKE®

An advanced version of the TriKE® platform that targets two different cancer antigens simultaneously, potentially increasing efficacy. (Represents a potential advancement in the company's product pipeline, aiming for improved therapeutic outcomes.)

Series L Convertible Preferred Stock

A class of preferred stock that can be converted into a fixed number of common shares under certain conditions. (A significant portion of the shares being registered for resale originate from the conversion of this preferred stock, indicating past financing and potential future dilution.)

Vested Warrants

Options that give the holder the right to purchase a company's stock at a specified price, which have met their vesting requirements. (Another major source of shares for resale, indicating previous equity issuances and potential for further dilution upon exercise.)

Pre-funded Warrants

A type of warrant that allows the holder to purchase a share of common stock for a nominal exercise price, often used in place of immediate stock issuance to avoid triggering certain ownership thresholds or for tax reasons. (These warrants, issued to PDPC Advisors Inc., represent a specific commitment and potential future issuance of shares.)

Going Concern

An accounting term indicating that a company is expected to remain in business for the foreseeable future, with the ability to meet its financial obligations. (The S-1 explicitly states substantial doubt about GT Biopharma's ability to continue as a going concern, a critical red flag for investors regarding financial stability.)

Greenshoe Rights

An over-allotment option granted by an issuer to an underwriter in an offering, allowing the underwriter to sell more shares than initially planned if demand is high. (The company has received $3.0 million from the exercise of these rights, indicating recent capital infusion, though the proceeds go to the company, not the selling stockholders.)

Year-Over-Year Comparison

This S-1 filing focuses on registering shares for resale, stemming from a recent private placement and warrant exercises, rather than reporting on operational performance compared to a prior period. Therefore, a direct comparison of key financial metrics like revenue growth, margin changes, or new risks from a previous filing is not feasible with the information provided in this document. The primary focus is on the implications of the current share registration and the company's precarious financial position, highlighted by the 'going concern' doubt.

Key Financial Figures

• $0.001 — 9,546 shares of common stock, par value $0.001 per share (the “Common Stock&rdqu
• $0.73 — ing sale price for our Common Stock was $0.73 per share. Investing in our securitie
• $6,611,111 — ants, with an aggregate stated value of $6,611,111.00, for an aggregate purchase price of
• $5,950,000.00 — .00, for an aggregate purchase price of $5,950,000.00 (the transactions contemplated by the S
• $24,018,349 — with an aggregate stated value of up to $24,018,349 (the “Greenshoe Rights”) fo
• $21,616,514 — uo;) for an aggregate purchase price of $21,616,514, subject to adjustments, as further des
• $3.0 million — ts to date before expenses are equal to $3.0 million. We intend to use the net proceeds from
• $250 million — reporting company” until we have $250 million or more in public float (based on our C
• $700 m — on our Common Stock) that is less than $700 million, annual revenues of $100 million
• $100 million — s than $700 million, annual revenues of $100 million or more during the most recently comple

Filing Documents

• forms-1.htm (S-1) — 711KB
• ex4-49.htm (EX-4.49) — 99KB
• ex5-1.htm (EX-5.1) — 14KB
• ex23-1.htm (EX-23.1) — 4KB
• ex107.htm (EX-FILING FEES) — 95KB
• forms-1_001.jpg (GRAPHIC) — 3KB
• ex5-1_001.jpg (GRAPHIC) — 4KB
• 0001493152-25-019296.txt ( ) — 1086KB
• ex107_htm.xml (XML) — 9KB

USE OF PROCEEDS

USE OF PROCEEDS 10 MARKET INFORMATION FOR SECURITIES AND DIVIDEND POLICY 11

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 12 SELLING STOCKHOLDERS 18 MATERIAL TAX CONSIDERATIONS 21 PLAN OF DISTRIBUTION 25 Incorporation of certain information by reference 27 WHERE YOU CAN FIND MORE INFORMATION 28 LEGAL MATTERS 28 EXPERTS 28 ABOUT THIS PROSPECTUS This prospectus is part of a registration statement filed with the U.S. Securities and Exchange Commission (the “SEC”) using a “shelf” registration process. By using a shelf registration statement, the Selling Stockholders may sell up to 14,589,546 shares of Common Stock from time to time in one or more offerings as described in this prospectus. We will not receive any proceeds from the sale by the Selling Stockholders of the shares of Common Stock offered pursuant to this prospectus. We may also file a prospectus supplement or post-effective amendment to the registration statement of which this prospectus forms a part that may contain material information relating to these offerings. The prospectus supplement or post-effective amendment may also add, update or change information contained in this prospectus with respect to that offering. If there is any inconsistency between the information in this prospectus and the applicable prospectus supplement or post-effective amendment, you should rely on the prospectus supplement or post-effective amendment, as applicable. Before purchasing any securities, you should carefully read this prospectus, any post-effective amendment, and any applicable prospectus supplement, together with the additional information described under the heading “ Where You Can Find More Information .” Neither we, nor the Selling Stockholders, have authorized anyone to provide you with any information or to make any representations other than those contained or incorporated by reference in this prospectus, any post-effective amendment, or any applicable prospectus supplement prepared by or on behalf of us or to which we have referred y

View Full Filing

View this S-1 filing on SEC EDGAR